13F Filings History of Commodore Capital LP

Latest 13F report
Q4 2025 - 17 Feb 2026
Value $
$1,502,245,473
Signature - Title
Michael Kramarz - Managing Partner
Location
New York, NY
Summary
This page shows a list of all the recent 13F filings made by Commodore Capital LP. Form 13F is required to be filed within 45 days of the end of a calendar quarter. Commodore Capital LP reported 33 stock holdings with total value $1,502,245,473 as of Q4 2025. Top holdings included RLAY, ALKS, TYRA, XENE, and SYRE.

Follow Filing Activity

Follow Commodore Capital LP and return when a new 13F portfolio filing appears.

This tracks SEC filing changes for this page using existing product update flows.

Sign up to follow filing activity
Holdings Value

Sponsored

Quick Takeaways

  • Commodore Capital LP reports institutional holdings through Form 13F filings.
  • Latest reported quarter: Q4 2025.
  • Latest reported holdings value: $1,502,245,473.

What Changed

  • Most recent filing was accepted on 17 Feb 2026, 16:05.
  • Reported value moved from $2,048,436,266 to $1,502,245,473.

Why This Matters

  • This gives a plain-language read of holdings direction before you open full quarter tables.
  • Use the filing links below to verify the exact SEC source document.

Official SEC Source

Backed by Form 13F

Portfolio holdings and changes are grounded in SEC Form 13F filings.

See Original Filing
Quarter Holdings Value $ Bought Sold Net Top Holdings Form Type Filing Time
Q4 2025 33 $1,502,245,473 +$146,112,414 -$1,292,601,361 -$1,146,488,947 RLAY, ALKS, TYRA, XENE, SYRE 13F-HR 17 Feb 2026, 16:05
Q3 2025 37 $2,048,436,266 +$361,796,321 -$229,917,294 +$131,879,027 MRUS, NUVL, XENE, COGT, ELVN 13F-HR 14 Nov 2025, 16:10
Q2 2025 33 $1,416,719,296 +$328,166,413 -$357,668,294 -$29,501,881 MRUS, NUVL, XENE, ELVN, AGIO 13F-HR 14 Aug 2025, 16:36
Q1 2025 31 $1,357,083,846 +$292,196,506 -$71,517,205 +$220,679,301 MRUS, NUVL, ELVN, SLNO, XENE 13F-HR 15 May 2025, 16:00
Q4 2024 31 $1,364,557,313 +$305,311,153 -$360,138,263 -$54,827,110 MRUS, PCVX, NUVL, XENE, ELVN 13F-HR 14 Feb 2025, 16:07
Q3 2024 36 $1,600,269,489 +$182,219,512 -$226,688,734 -$44,469,222 MRUS, VERA, XENE, PCVX, ELVN 13F-HR 14 Nov 2024, 15:45
Q2 2024 35 $1,465,008,171 +$311,596,307 -$248,255,919 +$63,340,388 MRUS, NUVL, XENE, PCVX, ELVN 13F-HR 14 Aug 2024, 16:25
Q1 2024 39 $1,495,487,511 +$300,342,925 -$296,302,110 +$4,040,815 MRUS, VERA, NUVL, XENE, SYRE 13F-HR 15 May 2024, 16:05
Q4 2023 32 $1,144,464,541 +$264,504,596 -$167,234,938 +$97,269,658 MRUS, XENE, NUVL, VERA, RYTM Restatement 14 Feb 2024, 16:38
Q3 2023 30 $855,509,177 +$153,938,217 -$119,541,865 +$34,396,352 MRUS, VERA, XENE, PCVX, COGT 13F-HR 14 Nov 2023, 16:00
Q2 2023 26 $889,839,183 +$223,081,879 -$132,878,612 +$90,203,267 MRUS, VERA, AKRO, XENE, COGT 13F-HR 14 Aug 2023, 16:00
Q1 2023 32 $656,834,859 +$170,942,983 -$107,374,156 +$63,568,827 XENE, VRDN, MRUS, COGT, BLU 13F-HR 15 May 2023, 16:06
Q4 2022 35 $663,544,000 +$167,172,158 -$118,388,162 +$48,783,996 XENE, VRDN, COGT, BLU, MRUS 13F-HR 14 Feb 2023, 11:00
Q3 2022 30 $601,204,702 +$136,688,800 -$59,662,237 +$77,026,563 COGT, XENE, VRDN, BLU, MRUS 13F-HR 14 Nov 2022, 16:00
Q2 2022 24 $453,358,635 +$113,777,462 -$50,517,323 +$63,260,139 MRUS, XENE, COGT, BLU, CYTK 13F-HR 15 Aug 2022, 17:02
Q1 2022 27 $447,722,000 +$109,841,449 -$46,296,761 +$63,544,688 MRUS, ACRS, BLU, ISEE, XENE 13F-HR 16 May 2022, 16:00
Q4 2021 25 $431,774,000 +$131,307,231 -$80,652,037 +$50,655,194 ISEE, MRUS, ACRS, XENE, CYTK 13F-HR 14 Feb 2022, 16:07
Q3 2021 29 $379,293,000 +$137,271,143 -$50,515,765 +$86,755,378 ISEE, ACRS, CYTK, DRNA, CCCC 13F-HR 15 Nov 2021, 16:02
Q2 2021 29 $287,021,000 +$75,392,477 -$45,829,699 +$29,562,778 ACRS, STSA, CELC, CCCC, CBAY Restatement 13 Oct 2021, 18:02
Q1 2021 31 $251,032,000 +$74,305,186 -$34,006,227 +$40,298,959 ACRS, CCCC, KURA, STSA, FPRX Restatement 13 Oct 2021, 17:58
Q4 2020 28 $183,931,000 $0 $0 $0 CCCC, TRILLIUM THERAPEUTICS INC, CNST, FPRX, KRON 13F-HR 16 Feb 2021, 16:13

Sponsored